18 F-THK5351 PET Findings Indicative of Reactive Astrogliosis in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.

Clin Nucl MedSep 24, 2026 (epub)
Case ReportNeurologyRadiology (Diagnostic)

Gen Yoshii, Keiko Hatano, Masashi Kameyama et al.

✦ AI-curated · Sources linked

Case in brief

A patient with autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) underwent 18F-THK5351 PET, 18F-FDG PET, and MRI. The 18F-THK5351 scan showed mild inflammatory lesions by imaging astrogliosis, while these lesions were difficult to detect on MRI. The report suggests that 18F-THK5351 PET may help identify inflammatory lesions in GFAP-A.

What made this case unusual

18F-THK5351 PET depicted mild inflammatory lesions associated with astrogliosis that were difficult to detect on MRI.

Diagnostic / clinical pearl

In GFAP-A, 18F-THK5351 PET may reveal inflammatory lesions that are subtle or difficult to detect on MRI.

Source

PubMed · PMID 42779508

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.